Video

Pharmacist Medication Insights: Shingrix for Herpes Zoster

Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses for the prevention of herpes zoster in adults aged 50 years and older.

Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses for the prevention of herpes zoster in adults aged 50 years and older.

The 2017 approval of Shingrix was based on phase 3 clinical trials that evaluated the vaccine's efficacy, safety, and immunogenicity in more than 38,000 people. In a pooled analysis of these studies, Shingrix demonstrated efficacy against shingles greater than 90% across all age groups, as well as sustained efficacy over a follow-up period of 4 years. By preventing shingles, Shingrix also reduced the overall incidence of postherpetic neuralgia, a form of chronic nerve pain and the most common complication associated with shingles.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com